• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

    2/14/24 2:14:48 PM ET
    $MTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTP alert in real time by email
    SC 13G/A 1 tm244732d13_sc13ga.htm SC 13G/A

     

    CUSIP No:    59564R708

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Biodexa Pharmaceuticals PLC

    (formerly Midatech Pharma PLC)

    (Name of Issuer)

     

    Ordinary Shares, nominal value £0.001 per share

    (Title of Class of Securities)

     

    59564R708

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No:    59564R708

     

    (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc. 

     
    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     
        (a)   ¨
    (b)   ¨
    (3)

    SEC USE ONLY

     

     
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING

    PERSON WITH

    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER **

     

    0

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER **

     

    0

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     
    (10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 

     
           ¨
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

     
    (12)

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO 

     

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:    59564R708

     

    (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     
    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     
        (a)   ¨
    (b)   ¨
    (3)

    SEC USE ONLY

     

     
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING

    PERSON WITH

    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER **

     

    0

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER **

     

    0

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     
    (10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 

     
           ¨
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0% 

     
    (12)

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO 

     

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:    59564R708

     

    Item 1.

     

    (a)Name of Issuer

     

    Biodexa Pharmaceuticals PLC (formerly Midatech Pharma PLC) (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom 

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the ordinary shares of the Company, nominal value £0.001 per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Ordinary shares, nominal value £0.001 per share

     

    Item 2(e) CUSIP Number

     

    59564R708. The CUSIP Number applies to the American Depositary Shares, each of which represents four hundred (400) Shares.

     

     

     

     

    CUSIP No:    59564R708

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
         
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

     

     

     

    CUSIP No:    59564R708

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No:    59564R708

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 12, 2024

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of   Name: Brian Sopinsky
    Attorney, a copy of which was   Title: Secretary
    previously filed    
         
    By: /s/ Brian Sopinsky      
    Name: Brian Sopinsky    
    Title: Secretary    

     

     

     

     

    CUSIP No:    59564R708 

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed 

     

     

     

    Get the next $MTP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease

      ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.BackgroundMany cancers exhibit high levels of metabolic plasticity, i.e. the ability to switch between energy-generating pathways in response to cellular stresses[1], such as those caused by chemotherapy. Highly proliferative cancers frequently use the aerobic glycolysis pathway, known as "the Warburg effect", to generate energy2. Oxidat

      3/27/23 8:20:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Results of General Meeting

      Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Company's Shareholder Circular and Notice of General Meeting (the "Circular") which

      3/24/23 8:00:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Further re: Notice of General Meeting

      Midatech Pharma PLC ("Midatech" or the "Company") Further re: Notice of General Meeting - Correction of Typographical ErrorsABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:· Resolution 4 of the Notice ("Resolution 4") refers to a proposed aut

      3/10/23 1:45:00 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    SEC Filings

    See more
    • SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      1/22/24 8:51:48 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      12/29/23 12:10:19 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Midatech Pharma PLC American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      12/26/23 4:53:52 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 8:47:28 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 2:42:24 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 2:14:48 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Financials

    Live finance-specific insights

    See more
    • Midatech Pharma PLC Announces Posting of Circular and Notice of General Meeting

      Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 8, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information.The

      3/8/23 2:20:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Leadership Updates

    Live Leadership Updates

    See more
    • Midatech Pharma PLC Announces Appointment of Nominated and Financial Adviser

      ABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect.Turner Pope Investments (TPI) Ltd will be the Company's sole broker.For further information, please contact:Midatech Pharma PLCStephen Stamp, CEO, CFOTel: +44 (0) 29 2048 0180www.midatechpharma.com Strand Hanson Limited (Nominated and Financial Adviser)James Dance / Matthew Chandler / Rob PatrickTel: +44 (0)20 7409 3494 Turner Pope Investments (TPI) Ltd (Broker)Andre

      3/8/22 5:00:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Appointment of Chief Scientific Officer

      Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific OfficerABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.Dr. Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Offic

      7/12/21 9:50:00 AM ET
      $MTP
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care